Volume 17, Number 9—September 2011
Research
Seroepidemiologic Study of Pandemic (H1N1) 2009 during Outbreak in Boarding School, England
Sandra Johnson, Chikwe Ihekweazu
, Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard G. Pebody, Graham Bickler, John T. Watson, and Éamonn O’Moore
, Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard G. Pebody, Graham Bickler, John T. Watson, and Éamonn O’Moore
Table 2
Association of demographic characteristics and interventions with study participants’ reports of ARI during outbreak of pandemic (H1N1) 2009 at a boarding school, England*
| Variable |
No. participants |
No. (%) with ARI |
Odds ratio (95% CI) |
|---|---|---|---|
| Total | 695 | 237 (34.1) | |
| Demographics | |||
| Category | |||
| Students | 469 | 187 (39.9) | 2.53 (1.75–3.65) |
| Staff | 226 | 50 (22.1) | 1 |
| Age group, y | |||
| 13–15 | 219 | 75 (34.2) | 1 |
| 16–18 | 250 | 112 (44.8) | 1.55 (1.06–2.28) |
| 20–49 | 111 | 32 (28.8) | 0.70 (0.42–1.15) |
| >50 | 87 | 18 (20.7) | 0.48 (0.26–0.86) |
| Sex, staff only† | |||
| F | 109 | 24 (22.0) | 1 |
| M | 117 | 26 (22.2) | 0.98 (0.52–1.83) |
| Role, staff only | |||
| Nonteaching | 135 | 26 (19.3) | 1 |
| Teaching |
85 |
23 (27.1) |
1.48 (0.78–2.82) |
| Interventions | |||
| Took antiviral drugs | |||
| No | 198 | 81 (40.9) | 1 |
| Yes | 393 | 110 (28.0) | 0.55 (0.38–0.79) |
| Use of antiviral drugs: PEP vs. treatment dose | |||
| No antiviral drugs | 198 | 81 (40.9) | 1 |
| Yes, PEP | 352 | 78 (22.2) | 0.40 (0.27–0.59) |
| Yes, treatment dose | 41 | 32 (78.1) | 4.87 (2.20–10.77) |
| Completion of PEP course of antiviral drugs† | |||
| No antiviral drugs | 198 | 81 (40.9) | 1 |
| Not completed | 51 | 14 (27.5) | 0.44 (0.17–1.15) |
| Completed | 294 | 62 (21.1) | 0.38 (0.22–0.65) |
| Seasonal Influenza vaccine | |||
| No | 216 | 66 (30.6) | 1 |
| Yes | 425 | 161 (37.9) | 1.35 (0.95–1.92) |
*Categories in which the response was missing or unknown are shown in the Table A1. ARI, acute respiratory infection; CI, confidence interval; PEP, postexposure prophylaxis.
†Excluding those who reported taking the treatment dose of antiviral drugs.
Page created: September 06, 2011
Page updated: September 06, 2011
Page reviewed: September 06, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.